(Q34279689)

English

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

Alzheimer's disease

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

Kaj Blennow

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1

object named as

Bengt Winblad

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lennart Minthon

3

object named as

Lennart Minthon

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Matthias Staufenbiel

10

object named as

Matthias Staufenbiel

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ralph P. Maguire

1 reference

ORCID Public Data File 2021

author name string

Niels Andreasen

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Annette Floesser

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Georges Imbert

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Thomas Dumortier

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

R Paul Maguire

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Joens Lundmark

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jean-Marc Orgogozo

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ana Graf

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

6 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

597-604

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

The worldwide societal costs of dementia: Estimates for 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-amyloid treatments in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid oligomers: formation and toxicity of Abeta oligomers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination Strategies for Alzheimer???s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid-beta immunisation for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Active and passive immunotherapy for neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970140-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(12)70140-0

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34279689&oldid=1694213750"